The potential of phospho‐GFAP or other PTMs as biomarkers for differential dementia diagnosis has not yet been explored, but based on research summarised above, phospho‐GFAP Serine 13 could be a potential FTLD‐specific biomarker test, and citrullinated GFAP may hold promise for AD and/or MS. Here, GFAP is linked to myeloid sarcoma.